Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Lu AE58054 in Patients With Mild to Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Idalopirdine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms STARBRIGHT
- Sponsors Lundbeck A/S
- 20 Jul 2017 Results (n=2525) from STAR Phase III Program (NCT01955161, NCT02006641, NCT02006654), presented at the Alzheimer's Association International Conference 2017.
- 13 Jan 2017 Status changed from active, no longer recruiting to completed.
- 22 Sep 2016 According to a Lundbeck media release, results of this trial are anticipated in the first quarter of 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History